14:00 - 14:15
Industry Presentation: Characterisation Of Biologics Through Functional Assays
Implementing biochemical and cellular functional assays within structured screening cascades, balancing biological relevance to identify, rank, and characterise biotherapeutics, and translating lead candidates into clinically relevant biotherapeutics.
14:15 – 14:30
Industry Presentation: Bringing Developability Into The Early Discovery Phase
What can and cannot be brought early into developability, how this feeds into AI/ML models for use in the design phase, and the next challenges that remain to be addressed.
14:30 - 14:45
Industry Presentation: Early-Stage Developability Assessment for Lead Optimization and Selection
Developability assessment for early-stage antibody leads, combining in silico analysis with in vitro assays. Covers high-throughput, sensitive assays for PK, biophysical, and immunogenicity profiling. Closes with forced degradation studies supporting risk mitigation and closed-loop decisions.
14:45 – 15:00
Next-Generation Stability, Characterisation & Developability: Building Confidence In Protein & Antibody Therapeutics From Discovery To Early Development
Functional assays for screening candidates to find therapeutic leads, characterising lead candidates and translating pre-clinical characteristics to clinical, bioanalytical challenges around characterisation to increase confidence and translation of a clinical candidate, integrating developability assessment and stability profiling early in development, and advancing analytical methods that are scalable and process-ready.
15:00
End of Technology Showcase
